Autolus director reports option on 80K ADS

Autolus Therapeutics plc director Ryan Richardson reported an initial holding of a share option covering 80,000 underlying American Depositary Shares.

Rhea-AI Filing Summary

Autolus Therapeutics plc director Ryan Richardson reported an initial holding of a share option covering 80,000 underlying American Depositary Shares. The option has an exercise price of $1.41 per share and expires on December 1, 2035. It vests in 36 equal monthly installments starting on January 1, 2026, meaning the right to buy the shares builds gradually over three years. This filing does not reflect a new stock purchase or sale, but discloses an existing equity award position.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Richardson Ryan

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--

Holdings After Transaction: Share Option (right to buy) — 80,000 contracts (Direct)

Footnotes (1)

1. F1. This option vested or vests in 36 equal monthly installments commencing on January 1, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Autolus (AUTL) Form 3 filed by Ryan Richardson show?

The Form 3 shows Ryan Richardson’s initial reported holding of a stock option for 80,000 underlying American Depositary Shares in Autolus. It establishes his baseline equity position as a director, with no indication of recent buying or selling activity.

How many Autolus (AUTL) shares are covered by Ryan Richardson’s option?

The option reported covers 80,000 underlying American Depositary Shares of Autolus Therapeutics plc. This represents the number of ADS that can be purchased if the option fully vests and is exercised according to its terms and schedule.

What is the exercise price and term of Ryan Richardson’s Autolus (AUTL) option?

The option has an exercise price of $1.41 per American Depositary Share and expires on December 1, 2035. This defines the fixed price at which he may buy shares during the option’s life, assuming vesting conditions are met.

How does Ryan Richardson’s Autolus (AUTL) option vest over time?

The option vests in 36 equal monthly installments starting January 1, 2026. This means one‑thirty‑sixth of the 80,000 underlying American Depositary Shares becomes exercisable each month over three years, rather than all at once.

Does Ryan Richardson’s Autolus (AUTL) Form 3 indicate recent insider buying or selling?

No, the Form 3 reflects a holding entry rather than a new transaction. It discloses an existing share option award position and its terms, without reporting open‑market purchases, sales, or other buy/sell activity in Autolus shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/23/2026 - 04:54 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Richardson Ryan

(Last) (First) (Middle)

C/O AUTOLUS THERAPEUTICS PLC

THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)

LONDON W12 7FP

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(1)	12/01/2035	American Depositary Shares	80,000	$1.41	D

Explanation of Responses:

1. This option vested or vests in 36 equal monthly installments commencing on January 1, 2026.

	/s/ Ryan Richardson	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)